GoodRx Expands Access to Eli Lilly's New Oral GLP-1 Foundayo and Zepbound KwikPen with Self-Pay Pricing at Over 70,000 Pharmacies

on

GoodRx partners with Eli Lilly to offer the newly FDA-approved oral GLP-1 medication Foundayo (orforglipron) to eligible self-pay patients starting at $149 per month.123

Zepbound (tirzepatide) KwikPen is available through GoodRx to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide.123

These offerings provide transparent pricing and nationwide access for oral and injectable GLP-1 treatments for obesity care outside traditional insurance.12

GoodRx helps manufacturers deliver consumer-direct pricing from launch, as stated by CEO Wendy Barnes.12

Sources:

1. https://www.businesswire.com/news/home/20260409583467/en/GoodRx-Expands-Access-to-Eli-Lilly-and-Companys-New-Oral-GLP-1-Foundayo-and-Zepbound-KwikPen-with-Self-Pay-Pricing-at-More-Than-70000-Pharmacies-Nationwide

2. https://www.benzinga.com/pressreleases/26/04/b51726076/goodrx-expands-access-to-eli-lilly-and-companys-new-oral-glp-1-foundayo-and-zepbound-kwikpen-with-

3. https://www.marketscreener.com/news/goodrx-enters-agreement-with-eli-lilly-and-company-to-expand-access-to-foundayo-and-zepbound-kwikpen-ce7e50d8db8ffe26